Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care Diagnostics, Global Health & Biosensors 2019

Paul Bohn's Biography



Paul Bohn, Arthur J. Schmitt Professor of Chemical and Biomolecular Engineering and Professor of Chemistry and Biochemistry, University of Notre Dame

Paul W. Bohn received the B.S. in Chemistry from the University of Notre Dame in 1977 and his Ph.D. in Chemistry from the University of Wisconsin-Madison in 1981. After two years at Bell Laboratories, Murray Hill, NJ, he joined the faculty at the University of Illinois at Urbana-Champaign (UIUC). In 2006, he left UIUC for the University of Notre Dame where he is currently the Arthur J. Schmitt Professor of Chemical and Biomolecular Engineering, Professor of Chemistry and Biochemistry, and Director of the Advanced Diagnostics & Therapeutics Initiative. He served as Editor for the Americas for the RSC journal Analyst 2007-09 and as Chair of the Editorial Board for 2010-14. Prof. Bohn has served on numerous editorial and scientific boards and is currently co-editor of Annual Review of Analytical Chemistry. His research interests include: (a) integrated nanofluidic and microfluidic chemical measurement strategies for personal monitoring, (b) chemical and biochemical sensing in mass-limited samples, (c) biochemical imaging, and (d) molecular approaches to nanotechnology, areas in which he has over 260 publications and 6 patents.

Paul Bohn Image

Multiplex Detection of Sepsis Biomarkers Enabled by Closed Bipolar Electrochemistry with Optical Readout

Tuesday, 8 October 2019 at 10:00

Add to Calendar ▼2019-10-08 10:00:002019-10-08 11:00:00Europe/LondonMultiplex Detection of Sepsis Biomarkers Enabled by Closed Bipolar Electrochemistry with Optical ReadoutPoint-of-Care Diagnostics, Global Health and Biosensors 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Sepsis syndrome affects close to 1,000,000 patients annually in the US alone. Of these ca. 30%, predominantly from the pediatric and geriatric populations, do not survive. In current practice, diagnosis is carried out using symptomatic indicators, which is problematic given the similarity of the symptoms to those of patients with influenza. What is needed is a rapid and accurate test that can distinguish where a patient is along the sepsis continuum, starting with systemic inflammatory response syndrome and ending at severe septic shock. We are developing microfluidically-enabled multiplex sensors capable of simultaneously discerning the presence and level of multiple biochemical markers of sepsis syndrome. The sensor relies on a unique assay, in which an electrochemical detection reaction is amplified by redox cycling in an analytical cell. This, in turn, is coupled to a complementary redox-cycled optical readout reaction in a separate reporter cell. Significant flexibility in design means that the readout can be tuned to the desired concentration range of the analyte, colorimetric readout for relatively high level metabolites, e.g. lactate, metal-deposition shifts in optical transmission of metamaterials for higher sensitivity, and fluorigenic reactions where maximum sensitivity is required, e.g. cytokines.


Add to Calendar ▼2019-10-07 00:00:002019-10-09 00:00:00Europe/LondonPoint-of-Care Diagnostics, Global Health and Biosensors 2019Point-of-Care Diagnostics, Global Health and Biosensors 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com